SHOWNOTES

This week on Telltales, Mike, Jason, and Hunt move from energy market crosscurrents into an AI-driven “SaaSpocalypse,” then close with high-stakes healthcare updates—from Lilly’s trillion-dollar run to PBM reform and early cancer detection.

[00:19] Disclaimer

Important investing and risk disclosure before the discussion begins.

[00:29] Exhibit C: Oil, Iran, and Geopolitical Risk

Crude holds in the mid-$60s as tensions around Iran and the Strait of Hormuz keep markets on edge. The team weighs U.S. posture, escalation scenarios, and what could force a near-term resolution.

[03:00] Exhibit B: Natural Gas Backwardation and Permian Pain

Natural gas pricing looks oddly soft despite a strong winter for demand, while Waha trades negative through cold weather. The group discusses upcoming pipeline capacity and what it could mean for Henry Hub and Gulf Coast pricing.

[04:36] Exhibit A: U.S. Finances, Defense Spending, and the Fed

A reality check on deficits, interest costs, and the limits of materially higher defense budgets. Hunt also discusses the Fed balance sheet, QT, and how lower short rates may not translate cleanly to long-bond relief.

[08:35] SaaSpocalypse: How AI Disrupts Software and Who Wins

The cost of writing code collapses, UI becomes less central, and the market rethinks what a software company actually is. They debate moats, distribution, sales vs. engineering, and why “when AI works, we just call it software.”

[12:21] Microsoft Office, File Formats, and Network Effects

Is the Office moat about features—or about interoperability and trust? Jason argues AI could dissolve file-format lock-in via on-the-fly conversion, while Mike counters that pros still need power tools and workflows.

[17:11] Big Tech Capex and AI Inference Demand

They connect massive data center spend (Amazon, Alphabet, Microsoft, Meta, Oracle) to rising inference usage rather than just training. The team frames this as both opportunity and disruption risk for incumbent SaaS.

[21:26] Is Tesla Overvalued? Robotaxis, Regulation, and Reality

A hands-on Full Self-Driving trip shapes Jason’s view that the technology is “extremely close,” shifting the bottleneck to regulation. They discuss what has to happen for robotaxi economics to justify Tesla’s valuation.

[24:18] Is Eli Lilly Overvalued? Weight Loss, Alzheimer’s, and Direct-to-Consumer

Lilly’s trillion-dollar milestone meets a cash-flow and durability debate: long patent lives, strong execution, and a surprisingly large share of prescriptions flowing through a direct-pay platform.

[26:00] PBMs in the Crosshairs

A bipartisan proposal targets vertically integrated PBM structures, with the group arguing that PBMs’ share of drug economics is distorting incentives. They explain why breaking up the model could shift profit pools back toward drugmakers and patients.

[27:29] Multi-Cancer Early Detection: Medicare Reimbursement Path

A policy update on potential Medicare reimbursement starting in 2028 for blood-based early cancer detection tests. Jason explains the “needle in a haystack” science and why earlier detection could improve outcomes and lower total costs.

[28:29] Vertex: Non-Opioid Pain and CF Competitive Landscape

They review Vertex’s pain medicine data as a meaningful step toward reducing opioid use in acute settings. The conversation also touches CF innovation and why some competing mRNA approaches have recently stalled.

[31:43] Harrow: CVS Formulary Coverage and Early Signals

Harrow lands CVS PBM formulary coverage and becomes the top prescribed dry-eye therapy within CVS workflows. Early prescription signals look promising, though the team notes data remains incomplete.

[32:41] Lantheus: Management Reset and Thesis Watch

A CEO change brings back leadership from the original investment era. They discuss pricing missteps, why the thesis may still hold, and what they’re watching next.

[33:29] BioNTech vs Moderna: Cash Discipline and Vaccine Economics

BioNTech’s cash preservation gets praise while Moderna navigates FDA review dynamics for its flu vaccine. A candid comment about U.S.-centric profitability highlights how much the U.S. subsidizes life-science innovation.

Thanks for listening—download the latest Cash Flow Memo at telltales.us and subscribe for next week’s continued discussion on AI disruption, energy, and healthcare.

This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com